【Joincare健康元是哪个国家的品牌？】

外推网助力Joincare健康元品牌出海！通过在本页面挂载Joincare健康元品牌的产品链接和联系邮箱，可以提高Joincare健康元产品曝光！跨境电商爆单神器，目前只要100元/年哦~

健康元药业集团股份有限公司（以下称健康元药业集团）前身为深圳太太保健食品有限公司。由朱保国董事长92年创办成立，靠一剂“太太口服液”奠定保健品行业龙头地位；95年战略转型进军药业，更名为深圳太太药业有限公司；97年收购深圳市海滨制药有限公司完成从保健品企业到制药企业成功转型；99年股份制改造完成变更为深圳太太药业股份有限公司；2001年太太药业上海证券交易所挂牌，成功上市，发行7,000万股，募集资金17亿，为当时A股上市募集资金最多的民营企业。之后，健康元药业集团相继收购健康药业（中国）有限公司，丽珠医药集团股份有限公司等优质医药企业；2003年更名为健康元药业集团股份有限公司。依靠多年来的专注医药领域的经营，健康元药业集团从一个知名的保健品企业已经发展成为国内综合实力雄厚的民营医药集团。

现健康元药业集团旗下三十余家主要控股子公司，500多种药品品种，员工8,000多人，业务范围涵盖保健品、原料药（含中间体）和制剂、处方药与非处方药、中成药与化学制剂、检测试剂等领域，并开始形成上下游产业链。保健品旗下拥有太太、静心、鹰牌等知名品牌；原料药（中间体）有抗生素系列及其中间体7ACA（酶法）、4AA、F9等；处方药包含消化道用药、心脑血管用药、抗感染用药、抗肿瘤药、神经脑血管用药、泌尿系统用药等领域；非处方药有胃肠道药品“丽珠得乐”、“丽珠肠乐”，口腔溃疡用药“意可贴”，感冒类药品“抗病毒口服颗粒”，皮肤外用药品“新肤螨灵软膏”、复方醋酸地塞米松乳膏等。2009年全国医院购药总量健康元药业集团在国内企业中排名第5，含外企排名第12（IMS数据显示）。健康元药业集团产品还远销美国、澳大利亚、新加坡、马来西亚、港澳台等地。

健康元药业集团子公司深圳市海滨制药有限公司以生产和销售抗生素为主，并把第三代抗生素碳青霉烯类作为主要发展方向，现已为全球最大的碳青霉烯类抗生素生产基地，为深圳市高新技术企业。继2011年海滨制药无菌美罗培南（原料药）通过欧盟GMP认证及2012年无菌美罗培南（注射用粉末）通过欧盟GMP认证，2014年初，海滨制药无菌美罗培南获得欧盟CEP证书，至此，海滨制药成为目前国内首家无菌美罗培南通过欧洲CEP认证的单位，也是目前国内同时拥有欧盟EU-GMP认证的无菌原料药、无菌制剂（注射用粉末）、欧洲CEP认证的无菌原料药三证合一的生产单位。

健康元药业集团2002年收购丽珠医药集团股份有限公司，成为丽珠医药集团第一大股东。2009年丽珠医药集团完成全国首家B股回购，健康元药业集团持股再次上升到45.31%。丽珠医药集团93年在深圳证券交易所成功发行A、B股，为国内首家同时发行A、B股的上市医药企业。丽珠医药集团产品包括化学原料药、化学制剂、中成药等共400多个品种，产品线丰富，品牌知名度广，在2009年7月国家新颁布的基本药物目录307个品种中，占九十余个品种，一百九十余个品规。

2007年健康元药业集团子公司焦作健康元生物制品有限公司全国首家环保“酶”法产业化生产医药抗生素—头孢菌素类的关键中间体7-氨基头孢烷酸（简称7-ACA），带领行业生产工艺从化学法向环保酶法转型，现已成为行业龙头。

健康元药业集团子公司新乡海滨药业有限公司生产美罗培南中间体4AA、F9，亚胺培南西司他丁等，现为新乡市重点企业，是深圳市海滨制药有限公司美罗培南中间体F9、4AA的主要供应厂家。

英文翻译：Jiankangyuan Pharmaceutical Group Co., Ltd. (hereinafter referred to as jiankangyuan Pharmaceutical Group) formerly known as Shenzhen Mrs. Health Food Co., Ltd. Founded in 1992 by Zhu Baoguo, chairman of the board of directors, and established the leading position in the health care industry with a single dose of "Madam oral liquid"; entered the pharmaceutical industry through strategic transformation in 1995, renamed Shenzhen madam Pharmaceutical Co., Ltd.; acquired Shenzhen Haibin Pharmaceutical Co., Ltd. in 1997, completed the successful transformation from the health care enterprise to the pharmaceutical enterprise; completed the joint-stock transformation in 1999, changed to Shenzhen madam Pharmaceutical Co., Ltd In 2001, Ma's pharmaceutical was listed on the Shanghai Stock Exchange and successfully listed. 70 million shares were issued and 1.7 billion capital was raised, which was the private enterprise that raised the most capital for A-share listing at that time. After that, jiankangyuan Pharmaceutical Group successively acquired health pharmaceutical (China) Co., Ltd., Lizhu Pharmaceutical Group Co., Ltd. and other high-quality pharmaceutical enterprises; in 2003, it was renamed jiankangyuan Pharmaceutical Group Co., Ltd. Relying on years of operation in the field of medicine, jiankangyuan Pharmaceutical Group has developed from a well-known health product enterprise into a private pharmaceutical group with strong comprehensive strength in China. At present, jiankangyuan Pharmaceutical Group has more than 30 major holding subsidiaries, more than 500 drug varieties, and more than 8000 employees. Its business scope covers health care products, APIs (including intermediates) and preparations, prescription drugs and over-the-counter drugs, proprietary Chinese medicine and chemicals, testing reagents and other fields, and began to form upstream and downstream industrial chains. Health care products have famous brands such as Madam, Jingxin, Yingpai, etc.; APIs (intermediates) include antibiotic series and intermediates 7aca (enzyme method), 4AA, F9, etc.; prescription drugs include gastrointestinal medicine, cardio cerebrovascular medicine, anti infective medicine, anti-tumor medicine, neuro cerebrovascular medicine, urinary system medicine, etc.; over-the-counter drugs include gastrointestinal medicine "Lizhu Dele"“ Lizhu Changle, oral ulcer medicine "yiketie", cold medicine "antiviral oral granules", skin external medicine "xinfujianling ointment", compound dexamethasone acetate cream, etc. In 2009, jiankangyuan Pharmaceutical Group ranked the 5th among domestic enterprises in terms of the total amount of drugs purchased by hospitals in China, including the 12th among foreign enterprises (according to IMS data). Our products are also exported to the United States, Australia, Singapore, Malaysia, Hong Kong, Macao and Taiwan. Shenzhen Haibin Pharmaceutical Co., Ltd., a subsidiary of jiankangyuan Pharmaceutical Group, mainly produces and sells antibiotics, and takes the third generation antibiotics carbapenem as the main development direction. Now it is the largest production base of carbapenem antibiotics in the world and a high-tech enterprise in Shenzhen. In 2011, aseptic meropenem (API) of Haibin pharmaceutical passed the EU GMP certification and in 2012, aseptic meropenem (powder for injection) passed the EU GMP certification. In early 2014, aseptic meropenem of Haibin pharmaceutical obtained the EU CEP certificate. So far, Haibin pharmaceutical has become the first unit in China that aseptic meropenem has passed the EU CEP certification, and also has the EU e at the same time It is a production unit with three certificates of sterile API, sterile preparation (powder for injection) certified by u-gmp and sterile API certified by European CEP. Jiankangyuan Pharmaceutical Group acquired Lizhu Pharmaceutical Group Co., Ltd. in 2002 and became the largest shareholder of Lizhu Pharmaceutical Group. In 2009, Lizhu Pharmaceutical Group completed the first B-share buyback in China, and jiankangyuan Pharmaceutical Group's shareholding rose to 45.31% again. In 1993, Lizhu Pharmaceutical Group successfully issued a and B shares on Shenzhen Stock Exchange, becoming the first listed pharmaceutical enterprise in China to issue a and B shares simultaneously. Lizhu Pharmaceutical Group's products include more than 400 varieties, including chemical APIs, chemical preparations, Chinese patent medicines, etc., with rich product lines and wide brand awareness. Among the 307 varieties newly issued by the state in July 2009, it accounts for more than 90 varieties and more than 190 specifications. In 2007, Jiaozuo jiankangyuan Biological Products Co., Ltd., a subsidiary of jiankangyuan Pharmaceutical Group, was the first environmental protection "enzyme" method industrialized to produce 7-aminocephalosporanic acid (7-ACA), a key intermediate of cephalosporins, which led the transformation of the industry production process from chemical method to environmental protection enzyme method, and has become the industry leader. Xinxiang Haibin Pharmaceutical Co., Ltd., a subsidiary of jiankangyuan Pharmaceutical Group, produces the intermediates 4AA and F9 of meropenem, imipenem and cistadine, etc. it is now a key enterprise of Xinxiang City and a major supplier of intermediates F9 and 4AA of Shenzhen Haibin Pharmaceutical Co., Ltd.

本文链接： https://www.waitui.com/brand/74062b4b9.html 联系电话：请联系客服添加